Thermo Fisher Scientific Expands Bioproduction Capabilities with New Bioreactor and Design Center
- Thermo Fisher Scientific launched the Gibco CTS DynaXS Single Use Bioreactor to enhance scalable cell therapy manufacturing.
- The company opened a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts, for comprehensive biologics support.
- These initiatives strengthen Thermo Fisher's position in cell and gene therapy, attracting clients in the biotechnology sector.
In a significant development for the pharmaceutical industry, Thermo Fisher Scientific (TMO) expands its bioproduction capabilities in early 2026. The company launches the Gibco CTS DynaXS Single Use Bioreactor, a product that will enable scalable manufacturing for cell therapy applications. This launch comes at a time when the demand for innovative treatments is rising, and optimizing production processes for therapeutic cells is more critical than ever.
Innovative Advances in Cell Therapy Production
The DynaXS bioreactor is designed specifically to meet the needs of companies involved in cell-based therapies. Its introduction aligns with the increasing complexity and specialization required in healthcare solutions. The capability for scalable manufacturing enhances the efficiency and reliability of therapeutic cell production, which is paramount for developers aiming to bring new therapies to market.
In conjunction with this product launch, Thermo Fisher opens a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. This state-of-the-art facility is equipped to provide a comprehensive suite of support for biologics development, managing processes from initial design to cGMP manufacturing. This dual initiative not only expands Thermo Fisher's service offerings but also solidifies its role as a significant player in the rapidly evolving field of cell and gene therapy.
Strengthening Bioproduction Capabilities
Thermo Fisher's enhancements are poised to attract a variety of clients who seek robust solutions for their bioproduction needs. By positioning itself as a competitive force in the biotechnology sector, the company becomes a key partner for firms exploring innovative cell and gene therapies.
Conclusion
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

